

225

wherein X is O or CH₂ and R, R³, R⁴ and R⁵ are as defined hereinafter
administered in co-therapy with atypical antipsychotics are useful in treating psychotic disorders

- 5 (I) an embodiment of the invention one or more compound(s) of formula (I)
administered in co-therapy with one or more atypical antipsychotic(s) are useful in
treating schizophrenia, schizophreniform disorder and/or schizoaffective disorder. In a
further embodiment of the invention one or more compound(s) of formula (I)
administered in co-therapy with one or more atypical antipsychotics are useful in
10 treating schizophrenia

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

- As used herein the term "psychotic disorder" shall include schizophrenia,
schizophreniform disorder, schizoaffective disorder, delusional disorder, brief
15 psychotic disorder, shared psychotic disorder, psychotic disorder due to a general
medical condition, substance-induced psychotic disorder, and psychotic disorder not
otherwise specified, schizophrenia. Preferably the term "psychotic disorders" shall
include schizophrenia, schizophreniform disorder, delusional disorder, brief psychotic
disorder, shared psychotic disorder, psychotic disorder due to a general medical
20 condition, substance-induced psychotic disorder, and psychotic disorder not otherwise
specified, schizophrenia. More preferably the "psychotic disorder" is schizophrenia.

- As used herein the term "schizophrenia" shall include schizophrenia,
catatonic-type schizophrenia, paranoid-type schizophrenia, disorganized type
25 schizophrenia and residual-type schizophrenia.

- As used herein the term "schizophreniform disorder" shall mean a disorder with
symptoms consistent with schizophrenia, but whose duration is not consistent with
schizophrenia.
30

As used herein the term "schizoaffective disorder" shall mean a disorder with
co-existing but independent schizophrenic (psychotic) and mood components.

- Treatment options for psychotic disorders including schizophrenia,
35 schizophreniform disorder, schizoaffective disorder and others include the
administration of typical or atypical antipsychotics and/or atypical antipsychotics.

22

226

compound of formula (I) and/or the amount of the atypical antipsychotic individually may or may not be therapeutically effective

As used herein the term "co-therapy" shall mean treatment of a subject in need thereof by administering one or more compounds of formula (I) with one or more atypical antipsychotics wherein the compound(s) of formula (I) and the atypical antipsychotic(s) are administered by any suitable means simultaneously sequentially separately or in a single pharmaceutical formulation. Where the compound(s) of formula (I) and the atypical antipsychotic(s) are administered in separate dosage forms the number of dosages administered per day for each compound may be the same or different. The compound(s) of formula (I) and the atypical antipsychotic(s) may be administered via the same or different routes of administration. The compound(s) of formula (I) and the atypical antipsychotic(s) may be administered via the same or different routes of administration. Suitable examples of methods of administration are orally intravenous (iv) intramuscular (im) and subcutaneous (sc). Compounds may also be administered directly to the nervous system including but not limited to the intracerebral intraventricular intracerebroventricular intrathecal intracisternal intraspinal and/or per-spinal routes of administration by delivery via intracranial or intravertebral needles and/or catheters with or without pump devices.

The compound(s) of formula (I) and the atypical antipsychotic(s) may be administered according to simultaneous or alternating regimens at the same or different times during the course of the therapy concurrently divided or single forms.

Optimal dosages and dosage regimens to be administered may be readily determined by those skilled in the art, and will vary with the mode of administration the strength of the preparation and the advancement of the disease condition. In addition factors associated with the particular patient being treated including patient's sex age weight diet physical activity time of administration and concomitant diseases will result in the need to adjust dosages and/or regimens.

As used herein the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts as well as any product which results directly or indirectly from combinations of the specified ingredients in the specified amounts.

226

227

Thus for treating a psychotic disorder a compound of formula (I) may be administered as co-therapy with one or more atypical antipsychotics. Preferably the compound of formula (I) is administered in amount in the range of about 10 to about 650 mg/day. More preferably the compound of formula (I) is administered in an amount in the range of about 10 to about 325 mg once or twice daily.

To prepare the pharmaceutical compositions of this invention one or more sulfamate compounds of formula (I) are intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques which carrier may take a wide variety of forms depending on the form of preparation desired for administration. e.g., i.v. sterile injectable formulations will be prepared using appropriate solubilizing agents. A unit dose would contain about 15 to 200 mg of the active ingredient. Topiramate is currently available for oral administration in round tablets containing 25 mg, 100 mg or 200 mg of active agent. The tablets contain some or all of the following inactive ingredients: lactose hydrous, pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, purified water, carnauba wax, hydroxypropyl methylcellulose, titanium dioxide, polyethylene glycol, synthetic iron oxide and polysorbate 80.

While the foregoing specification teaches the principles of the present invention with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.

228